摘要
目的:比较格列美脲和格列本脲的有效性和安全性。方法:通过检索国内外1995~2013年发表的关于格列美脲和格列本脲治疗2型糖尿病的中英文文献,并以Jadad评分标准结合Cochrance简单评价方法评价纳入文献的研究质量,对纳入的文献使用Review Manager 5.0进行Meta分析。结果:共检索文献45篇,按照纳入和排除标准,最终筛选12篇进行Meta分析。有效性Meta分析,格列美脲在HbA1c、FBG、2hPBG方面与格列本脲差异无统计学意义(P〉0.05);安全性Meta分析,格列美脲与格列本脲在低血糖发生率方面有显著差异(P〈0.05),格列美脲组低血糖发生率显著低于格列本脲组。结论:格列美脲与格列本脲治疗2型糖尿病疗效相当,但格列美脲低血糖发生率低于格列本脲,可能更安全。
Objective: Compare the efficacy and security of glimepiride and glyburide. Methods: Inputs for the Meta-analysis were chosen from the literature published both in the domestic and overseas during 1995 to 2013 about glimepiride and glyburide in the treatment of T2DM by using Jadad grading standard and Cochrance review. Review Manager 5. 0 was used to conduct the Meta-analysis of chosen literature. Results: Twelve literature( 8 in Chinese,4 in English) were chosen from all the 45 retrieved papers according to exclude and inclusive criterias. Efficacy: the results showed that there were no differences between two groups in glycosylated hemoglobin,fasting and postprandial plasma glucose( P〉 0. 05). Security: the results showed that there were significantly differences between two groups in incidence of hypoglycemia( P 〈0. 05). Glimepiride has lower incidence of hypoglycemia as compared with glyburide. Conclusion: Glimepiride and glyburide had therapeutic equivalence. However glimepiride had a lower incidence of hypoglycemia than glyburide and more security.
出处
《中国药物评价》
2014年第2期99-106,共8页
Chinese Journal of Drug Evaluation